[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-valve-insufficiency-and-aortic-valve-insufficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-valve-insufficiency-and-aortic-valve-insufficiency":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,49],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100508060","study-on-efficacy-safety-and-durability-of-the-uniline-prosthesis-in-the-treatment-of-aortic-and-mitral-valve-disease-100508060",false,"NCT05895487","Study on Efficacy, Safety and Durability of the UniLine Prosthesis in the Treatment of Aortic and Mitral Valve Disease","Multicentered Observational Cohort Study on the Efficacy, Safety and Durability of the \"UniLine\" Epoxy-treated Prosthesis Made With Xenopericardium in the Treatment of Isolated Aortic and Mitral Valve Disease (UniLine RetroFit)","Inclusion Criteria:\n\n* Patients of both sexes aged 18 years and older who underwent isolated mitral or aortic valve replacement using the \"UniLine\" bioprosthesis\n* No prior heart valve replacement\n\nExclusion Criteria:\n\n* The presence of a mechanical or biological prosthesis in another position\n* Prior valve repair\n* Aortic aneurysm repair (ascending aorta)\n* Resection of a left ventricular aneurysm\n* Patients with active cancer and patients with history of cancer","ALL","18 Years",{"count":19,"type":20},2000,"ESTIMATED","OBSERVATIONAL","Acquired heart diseases continue to remain one of the most common causes of cardiac mortality and morbidity. In the Russian Federation, open surgery treatment of acquired valvular heart diseases (AVHD) is performed in more than 40 regions by specialists from 92 healthcare organizations.\n\nTreating aortic or mitral valve disease using the \"UniLine\" biological prosthesis is expected to improve survival rates. Supposedly, in vivo the \"UniLine\" biological prosthesis will show optimal hemodynamic characteristics and high resistance to structural valve degeneration and infectious damage, thus lowering the risk of dysfunction. Moreover, the risk of repeated intervention due to dysfunction of the \"UniLine\" bioprosthesis should not exceed the risk of the primary implantation. Supposedly, in the case of dysfunction of \"UniLine\" bioprosthesis it would be possible to perform repeated replacement using valve-in-valve technique.\n\nThe aim of the study is to assess the effectiveness, safety, durability of the \"UniLine\" epoxy-treated prosthesis and the long-term outcome of the treatment of isolated mitral and aortic valve diseases using this prosthesis.\n\nIn accordance with the objectives and hypothesis, the following data will be analyzed: actuarial and linear survival rates (general and cardiac), non-lethal prosthesis-associated complications, prosthetic dysfunction and repeated interventions.\n\nMoreover, in vivo hemodynamic parameters of the prosthesis will be assessed: the area of the effective opening surface, peak and mean gradient of pressure and blood flow velocity.\n\nThe study will be conducted at the Research Institute of Complex Issues of Cardiovascular Diseases. Study protocol received sponsorship approval and approval by Local Ethics Committee of the Research Institute and Research Coordinating Committee. The study will enroll patients who underwent isolated mitral or aortic valve replacement; transthoracic echocardiography will be conducted in all patients available for in-person visit.",[24,25,26,27,28],"Diseases of Mitral and Aortic Valves","Rheumatic Disorders of Mitral and Aortic Valves","Other Congenital Malformations of Aortic and Mitral Valves","Valvular Heart Disease (Aortic and Mitral Valves)","Mitral Valve Insufficiency and Aortic Valve Insufficiency",[30,31,32,33,34,35],"acquired heart diseases","mitral valve","aortic valve","prosthetic heart valves","bioprosthetic valves \"UniLine\"","bioprosthetic valve dysfunction","RECRUITING","2024-09-24",{"date":39,"type":40},"2024-09-26","ACTUAL",{"date":42,"type":40},"2022-11-01",{"date":44,"type":20},"2026-05-01",{"name":46,"class":47},"Closed Joint-Stock Company NeoCor","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":73,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":48},"100534173","european-association-of-cardiovascular-imaging-multiple-and-mixed-valvular-disease-study-100534173","NCT06235385","European Association of Cardiovascular Imaging Multiple and Mixed Valvular Disease Study","EACVI-MMVD","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patient referred to the cardiovascular imaging department.\n3. Diagnosis of MMVD confirmed by transthoracic echocardiography, defined as:\n\n   1. Multiple VHD: at least 2 moderates to severe VHD involving ≥ 2 different valves, using the current ESC guidelines.\n\n      and\u002For\n   2. Mixed VHD: at least moderate stenosis and at least moderate regurgitation of a single valve, using the current ESC guidelines.\n4. Patient not refusing to have their data involved in the protocol after information.\n\nExclusion Criteria (patients fulfilling any of the following criteria are not eligible for inclusion in this study):\n\n1. History of prior valve surgery or percutaneous valve intervention (concerning a valve other than those involved in the definition of MMVD).\n2. Acute infective endocarditis at the time of evaluation for inclusion (confirmed according to modified Duke criteria) or history of endocarditis ≤ 6 months.\n3. Complex congenital heart diseases.",{"count":57,"type":20},1500,"This study aims to investigate the prevalence and characteristics of multiple and mixed valvular heart disease (MMVD), which includes combinations of stenotic or regurgitant lesions on cardiac valves. The research will be conducted as a multicenter observational study, involving several centers worldwide, and will have a one-year follow-up period (with a possible extension to 5 years). The primary aim is to determine the proportion of MMVD among patients evaluated for valvular heart disease. Secondary aims include the evaluation of the epidemiologic distribution of clinical, biological, and cardiovascular imaging characteristics at baseline, management strategies, and their impact on prognosis. The study will also evaluate clinical outcomes such as mortality, hospitalization for heart failure, and changes in echocardiographic parameters. This research aims to provide valuable insights into the diagnosis, management, and prognosis of MMVD, addressing an important knowledge gap in this area.",[60,61,62,63,64,65,66,28,67,68,69,70,71,72],"Heart Valve Diseases","Multiple Valve Disease, Unspecified","Aortic Valve Disease","Aortic Valve Stenosis","Aortic Valve Insufficiency","Mitral Valve Disease","Mitral Valve Stenosis","Mitral Valve Insufficiency","Aortic Valve Stenosis With Insufficiency","Mitral Valve Disease Mixed","Tricuspid Valve Insufficiency","Tricuspid Valve Disease","Tricuspid Stenosis",[74,75],"Multiple Valvular Heart Disease","Mixed Valvular Heart Disease","2024-05-31",{"date":78,"type":40},"2024-06-03",{"date":80,"type":40},"2024-02-07",{"date":82,"type":20},"2029-08-01",{"name":84,"class":47},"Assistance Publique - Hôpitaux de Paris"]